Natera director-linked trusts sell 18,064 shares
The trust sales were made under a Rule 10b5-1 plan adopted by Sheena Jonathan on June 11, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Natera, Inc. (NTRA) director and co-founder Sheena Jonathan reported sales of 18,064 common shares by Caraluna 1 Trust and Caraluna 2 Trust on September 23, 2026, across 12 transactions. The sales were made under a Rule 10b5-1 trading plan adopted on June 11, 2026. The trusts held the shares for their beneficiaries, and Jonathan disclaimed beneficial ownership.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2, F3 | 400 | $385.1025 | $154K |
| Sale | Common Stock F1, F4, F3 | 2,175 | $386.7144 | $841K |
| Sale | Common Stock F1, F5, F3 | 2,734 | $387.6545 | $1.06M |
| Sale | Common Stock F1, F6, F3 | 1,293 | $388.7071 | $503K |
| Sale | Common Stock F1, F7, F3 | 2,320 | $389.685 | $904K |
| Sale | Common Stock F1, F3 | 110 | $390.42 | $43K |
| Sale | Common Stock F1, F8, F3 | 390 | $385.2906 | $150K |
| Sale | Common Stock F1, F9, F3 | 2,300 | $386.6396 | $889K |
| Sale | Common Stock F1, F10, F3 | 2,846 | $387.7351 | $1.10M |
| Sale | Common Stock F1, F11, F3 | 1,341 | $388.7637 | $521K |
| Sale | Common Stock F1, F12, F3 | 1,935 | $389.7108 | $754K |
| Sale | Common Stock F1, F13, F3 | 220 | $390.525 | $86K |
| Holding | Common Stock | -- | -- | -- |
Footnotes (13)
- F1. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2026.
- F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $385.0350 to $385.1900 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. Held for the benefit of the beneficiaries of the trust. The Reporting Person disclaims beneficial ownership over such securities.
- F4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $386.1750 to $387.1700 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $387.21 to $388.12 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $388.3050 to $389.0400 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F7. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $389.3650 to $390.2850 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F8. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $385.0350 to $386.0150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F9. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $386.17 to $387.16 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F10. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $387.21 to $388.19 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F11. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $388.35 to $389.33 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F12. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $389.3650 to $390.2050 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F13. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $390.42 to $390.63 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
beneficial ownership regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.